Navigation Links
Lung Cancer Alliance Issues Statement on FDA Tobacco Regulation Bill
Date:6/12/2009

Urges Comprehensive Approach to Addressing Lung Cancer

WASHINGTON, June 12 /PRNewswire-USNewswire/ -- Today, the U.S. House of Representatives overwhelmingly endorsed the U.S. Senate version of the FDA tobacco regulation bill with a 307-97 vote -- an emphatic exclamation point for the successful conclusion of a decade long battle.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO)

The final stop is the President's desk and a signing ceremony is expected to be held next week.

Lung Cancer Alliance President Laurie Fenton Ambrose called its passage an historic moment in public history.

"This legislation recognizes that nicotine is a highly addictive drug that tobacco companies have deliberately used fraudulent and deceptive marketing to hook new smokers as young as possible, and must be regulated as the dangerous drug it is." she said.

"Hopefully this will help the millions of current smokers to finally quit once and for all," she said.

"And, hopefully too this will mark a new beginning for lung cancer research and early detection. Already over half of new cases are being diagnosed in former smokers and another 15% have never smoked at all," she pointed out.

"We have to stop blaming and start addressing the disease of lung cancer in its entirety. I believe that President Obama understands this and will start moving public health policy in this direction."

Lung Cancer Alliance (www.lungcanceralliance.org) is the only national non-profit organization solely dedicated to patient support and advocacy for the lung cancer community. LCA's mission is to lead the movement to reverse decades of stigma and neglect by empowering those with or at risk for the disease, elevating awareness and changing health policy.

    Media Contact:
    Kay Cofrancesco
    kay@lungcanceralliance.org
    202-463-2080



'/>"/>
SOURCE Lung Cancer Alliance
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... 06, 2016 , ... Experimentation involving human stem cells (HSCs) ... to its potential for revolutionizing human disease treatment. There are multiple HSC platforms ... cells (hiPSCs). , Both platforms have distinct advantages and disadvantages, but what ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder supplement has a ... world’s most powerful antioxidants, molecular hydrogen, HydroFX for Water transforms every day ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... TopConsumerReviews.com recently ... Mobility Scooters . , Mobility Scooters give freedom to people who need help ... Still others may be facing a long period of rehabilitation after an illness or ...
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is ... natural lighting effect without heavy rendering or complicated compositing," said Christina Austin - CEO ... to create an organic spectrum of lights that simulates the look of a glare. ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... and relationship-marketing firm, announced today that nominations will be accepted from December ... (ISE®) Central Awards. , Awards include the Information Security Executive® of the ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... CRANBURY, N.J. , Dec. 5, 2016 /PRNewswire/ ... pharmaceutical company, today presented data from two Phase ... poster sessions at the 58th annual meeting of ... San Diego, California . The two ... patients with acute myeloid leukemia (AML) and T-cell ...
(Date:12/5/2016)... Dec. 5, 2016   Lexicon Pharmaceuticals, Inc. ... from a Phase 2 clinical study of sotagliflozin, a ... collaboration with JDRF, the leading global organization funding type ... Phase 2 clinical trial, which randomized a total of ... once-daily 400 mg dose of sotagliflozin compared to a ...
(Date:12/5/2016)... 5, 2016  Sharn Anesthesia Inc. announced today that ... distribution partner for Salter Labs.  The company also received ... recognition of outstanding sales performance. Salter Labs ... anesthesia care, including the market gold standard ECO 2 ... distributor of the Parker Flex-Tip® Endotracheal Tube, which is ...
Breaking Medicine Technology: